Loading...
•
Dec 31, 2021
Journey Medical Q4 2021 Earnings Report
Reported full-year 2021 financial results and recent corporate highlights.
Key Takeaways
Journey Medical reported record net product revenues of $63.1 million for the full year 2021 and completed its initial public offering, raising $30.6 million in net proceeds.
Generated record net product revenues of $63.1 million for the full year 2021.
Completed initial public offering of common stock and raised $30.6 million in net proceeds.
Dosed first patient in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea.
Expanded dermatologic footprint to include nine marketed dermatology products and have pivotal Phase 3 clinical program underway for DFD-29.
Forward Guidance
Journey Medical is well-positioned for continued growth in 2022 and beyond due to a strong financial foundation, a seasoned dermatology sales force and leadership team, and a strategic development pipeline.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...